Mood & neurochemistry
Thirty years of drug development aimed at plaques. The plaques are real and visible; that they are the CAUSE is the part still contested.
Not yet investigated
Thirty years of drug development aimed at plaques. The plaques are real and visible; that they are the CAUSE is the part still contested.
This star is on the map because the show intends to take the question apart properly — the trials, how it is actually tested, whether the thing sold is the thing studied. That work is not done yet, and nothing here should be read as a conclusion. When the investigation is published it will appear on this page.
What we are reading
Gathered for the investigation and not yet written up. Each note says what the paper does and does not show.
The serious, peer-reviewed challenge — and far stronger ground than 'the plaques were made up'. Reviewing RCTs of eight anti-amyloid antibodies, the authors argue the fall in amyloid PET signal is UNLIKELY to be a one-to-one measure of amyloid removal, and may instead reflect therapy-related brain damage, pointing to the raised incidence of ARIA and the reported loss of brain volume. They call on the FDA to PAUSE existing and new approvals pending phase 4 data. George Perry is among the authors. This is the citation for a critical episode; the retraction of Abeta*56 is a separate and narrower point.
Also in Mood & neurochemistry
The letter
The full citation list for each investigation, the studies that didn't make the episode, and any corrections — sent the morning it publishes.
No sponsors · No supplement affiliates · Unsubscribe any time
